Bank of New York Mellon’s Ascendis Pharma A/S ASND Stock Holding History

Bank of New York Mellon’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$85.2M	Buy	319,412 +90,737	+40%	+$21.2M	0.01%	755
2026 Q1	$52.3M	Buy	228,675 +34,070	+18%	+$7.64M	0.01%	971
2025 Q4	$41.5M	Sell	194,605 -14,693	-7%	-$3.03M	0.01%	1122
2025 Q3	$41.6M	Buy	209,298 +91,682	+78%	+$17.1M	0.01%	1136
2025 Q2	$20.3M	Buy	117,616 +28,407	+32%	+$4.63M	﹤0.01%	1512
2025 Q1	$13.9M	Sell	89,209 -9,183	-9%	-$1.31M	﹤0.01%	1692
2024 Q4	$13.5M	Sell	98,392 -6,826	-6%	-$897K	﹤0.01%	1774
2024 Q3	$15.7M	Sell	105,218 -5,423	-5%	-$732K	﹤0.01%	1708
2024 Q2	$15.1M	Sell	110,641 -40,303	-27%	-$5.48M	﹤0.01%	1737
2024 Q1	$22.8M	Sell	150,944 -62,225	-29%	-$8.88M	﹤0.01%	1501
2023 Q4	$26.8M	Sell	213,169 -19,593	-8%	-$1.95M	0.01%	1447
2023 Q3	$21.8M	Sell	232,762 -83,234	-26%	-$7.79M	﹤0.01%	1496
2023 Q2	$28.2M	Buy	315,996 +70,577	+29%	+$6.14M	0.01%	1362
2023 Q1	$26.3M	Sell	245,419 -5,231	-2%	-$598K	0.01%	1396
2022 Q4	$30.6M	Sell	250,650 -10,791	-4%	-$1.25M	0.01%	1303
2022 Q3	$27M	Sell	261,441 -8,505	-3%	-$806K	0.01%	1318
2022 Q2	$25.1M	Sell	269,946 -19,398	-7%	-$1.83M	0.01%	1414
2022 Q1	$34M	Buy	289,344 +49,298	+21%	+$5.71M	0.01%	1355
2021 Q4	$32.3M	Sell	240,046 -2,087	-0.9%	-$310K	0.01%	1430
2021 Q3	$38.6M	Sell	242,133 -20,837	-8%	-$2.85M	0.01%	1309
2021 Q2	$34.6M	Buy	262,970 +156	+0.1%	+$20.8K	0.01%	1414
2021 Q1	$33.9M	Buy	262,814 +100,790	+62%	+$15.3M	0.01%	1383
2020 Q4	$27M	Buy	162,024 +9,831	+6%	+$1.63M	0.01%	1445
2020 Q3	$23.5M	Buy	152,193 +15,156	+11%	+$2.18M	0.01%	1373
2020 Q2	$20.3M	Buy	137,037 +9,820	+8%	+$1.35M	0.01%	1433
2020 Q1	$14.3M	Sell	127,217 -6,900	-5%	-$897K	﹤0.01%	1500
2019 Q4	$18.7M	Buy	+134,117	New	+$14.9M	﹤0.01%	1612
2019 Q1	–	Sell	-123,415	Closed	-$7.73M	–	4211
2018 Q4	$7.73M	Buy	+123,415	New	+$7.75M	﹤0.01%	2056

Other funds holding ASND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

BSA

Braun Stacey Associates New York $3.53B AUM 63.32% 1-Year Est. Return

Bank of New York Mellon's ASND Position: Q2 2026 in Review

Bank of New York Mellon increased its Ascendis Pharma A/S (ASND) stake by 40% in Q2 2026, buying an estimated $21.2M and bringing the position to 319,412 shares worth $85.2M. The position accounts for 0.01% of the portfolio, ranked #755.

Bank of New York Mellon first reported a position in ASND in Q4 2018 and has held it in 28 quarters since. 120 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Bank of New York Mellon held 319,412 shares of Ascendis Pharma A/S worth $85.2M as of Q2 2026.
Bank of New York Mellon bought 90,737 Ascendis Pharma A/S shares in Q2 2026, an estimated $21.2M.
Ascendis Pharma A/S made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #755 holding.
Bank of New York Mellon first reported a position in Ascendis Pharma A/S in Q4 2018 and has held it in 28 quarters since.
120 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.